Discover our latest article, titled Randomized phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced soft-tissue sarcoma.
We very much look forward to attending the @Society for Immunotherapy of Cancer Annual Meeting in Boston from November 8 to 12, and to showcasing our recent research works through our posters. Plan to stop by to talk of them and about your research programs.
Discover our latest paper, titled Pembrolizumab combined with low-dose cyclophosphamide and intra-tumoral injection of the toll-like receptor 4 agonist G100 in patients with advanced pretreated soft tissue sarcoma: results from the PEMBROSARC basket study
Discover our latest publication, which helps predict the survival of cancer patients treated with immune checkpoint inhibitors.
Here is our latest publication, titled A novel gut-restricted small molecule TLR2 agonist enhances immune checkpoint inhibitor efficacy in a preclinical mouse fibrosarcoma tumor model.
Discover our main news for the first half of 2022! Hear about the great opportunity that is our partnership with Domain Therapeutics, new cutting-edge platforms for biomarker translational research as well as our newest featured publication!
Here is our latest publication, titled Mature tertiary lymphoid structure is a specific biomarker of cancer immunotherapy and does not predict outcome to chemotherapy in non-small cell lung cancer.
Ovarian cancer ascites are a remarkable opportunity to improve your translational research and therapeutic testing!
In this collaborative work, researchers from Institut Bergonié, Institut Gustave Roussy, and Explicyte, demonstrated that presence of APAP in plasma from cancer patients before they undergo immunotherapy was independently associated with a worse clinical outcome.
As Olink®-certified service Provider, Explicyte offers now high proteomic analysis capabilities for comprehensive protein biomarker discovery using Olink® Target technology.
The GeoMx Whole Transcriptome Atlas (WTA) empowers to explore biology accross a tissue. The human whole transcriptome (over 18,000 protein-coding human genes) is measured in each region of interest to uncover biological changes at specific locations of the tissue.
The GeoMx Whole Transcriptome Atlas delivers the maximum amount of sensitivity and confidence in each transcript through its unique probe architecture. The WTA profiles over 18,000 protein-coding human genes based on the human gene nomenclature committee (HUGO1) database cross-referenced with available mRNA sequences in the National Center for Biotechnology’s Information (NCBI) RefSeq database.
The WTA then allows to explore pathways across the whole transcriptome in defined regions of interest.
- Whole transcriptome coverage with probes specific to protein coding mRNA sequences
- Compatible with common sample types such as formalin-fixed paraffin embedded (FFPE) or fresh frozen (FF) tissue and across all human tissues types
- Superior sensitivity to detect 1000s of unique human genes in <50 μm regions
- Robust performance across sample types including FFPE with high concordance with RNA-seq and RNAscope™
- Map single cell RNA-seq populations to their tissue location
The GeoMx Whole Transcriptome Atlas delivers the maximum amount of sensitivity and confidence in each transcript through its unique probe architecture. The WTA profiles over 18,000 protein-coding human genes based on the human gene nomenclature committee (HUGO1) database cross-referenced with available mRNA sequences in the National Center for Biotechnology’s Information (NCBI) RefSeq database.
The WTA then allows to explore pathways across the whole transcriptome in defined regions of interest.
Learn about out Digitial Spatial Profiling (DSP) services
The Cancer Transcriptome Atlas (CTA) is designed for comprehensive profiling of the tumor biology, tumor microenvironment, and the immune response. It covers the RNA expression of over 1,800 genes simultaneously with spatial resolution in any region of interest from a single tissue section.
The CTA assay is compatible with RNAscope® and antibody visualization markers. It can also be supplemented with up to 60 additional targets of interest.
- Extensive coverage of the immune response, tissue microenvironment, tumor biology, and genes from clinically relevant genes sets such as tumor inflammation
- Spatial measurement of single cell signatures with high sensitivity and dynamic range
- Inclusion of genes for the Tumor Inflammation Signature, PAM50 and other clinical signatures
- Over 100 pathways to explore all aspects of cancer and tumor biology
Learn about out spatial transcriptomics services
Comprehensively Annotated Pathways in the CTA
| Adaptive Immunity | | Cell Function | | Signaling Pathways |
| T cells B cells | Apoptosis | AMPK Signaling | ||
| TCR & BCR Signaling | Autophagy | Androgen Signaling | ||
| Cancer Antigens | Cell Adhesion & Motility | EGFR Signaling | ||
| MHC Class I & II Antigen Presentation | Cell Cycle | ERBB2 Signaling | ||
| T-cell Checkpoints | Cilium Assembly | Estrogen Signaling | ||
| TH1, TH2, TH9, Th17, and Treg Differentiation | Differentiation | FGFR Signaling | ||
| DNA Damage Repair | FoxO Signaling | |||
| Innate Immunity | EMT | GPCR Signaling | ||
| Complement System | Endocytosis | Hedgehog Signaling | ||
| Dendritic Cells | Epigenetic Modification | HIF1 Signaling | ||
| DNA & RNA Sensing | Immortality & Stemness | Insulin Signaling | ||
| Glycan Sensing | Ion Transport | JAK-STAT Signaling | ||
| Host Defense Peptides | Lysosome | MAPK Signaling | ||
| Inflammasomes | Oxidative Stress | MET Signaling | ||
| Myeloid Inflammation | Phagocytosis | mTOR Signaling | ||
| Neutrophil Degranulation | Proteotoxic Stress | Myc | ||
| NK Activity | RNA Processing | NO Signaling | ||
| NLR Signaling | Senescence | Notch Signaling | ||
| RAGE Signaling | p53 Signaling | |||
| TLR Signaling | Metabolism | PDGF Signaling | ||
| Amino Acid Synthesis & Transport | PI3K-Akt Signaling | |||
| Immune Response | Arginine & Glutamine Metabolism | PPAR Signaling | ||
| Chemokine Signaling | Fatty Acid Oxidation & Synthesis | Purinergic Signaling | ||
| Cytotoxicity | Glycolysis & Glucose Transport | Retinoic Acid Signaling | ||
| IL-1, IL-2, IL-6 & IL-17 Signaling | Glycosylation | TGF-beta Signaling | ||
| Immune Exhaustion | IDH1/2 | VEGF Signaling | ||
| Interferon Response Genes | Lipid Metabolism | Wnt Signaling | ||
| Lymphocyte Regulation & Trafficking | Mitochondrial Metabolism / TCA | |||
| NF-kB Signaling | Nucleotide Synthesis | Physiology & Disease | ||
| Other Interleukin Signaling | Pentose Phosphate | Angiotensin System | ||
| Prostaglandin Inflammation | Tryptophan & Kynurenine Metabolism | Circadian Clock | ||
| TNF Signaling | Vitamin & Cofactor Metabolism | Drug Resistance | ||
| Type I, II, & III Interferon Signaling | | Glioma | ||
| | Leukemia | |||
| Matrix Remodeling and Metastasis | ||||
| Melanoma | ||||
| Neuroendocrine Function | ||||
| Prostate Cancer |